Apellis Pharmaceuticals' pegcetacoplan (APL-2) was evaluated in a Phase 2 clinical trial for amyotrophic lateral sclerosis (ALS). The study aimed to assess its efficacy and safety over 24 months. Despite the potential of pegcetacoplan as a complement inhibitor, the trial was terminated after failing to meet primary and key secondary endpoints at Week 52. This outcome raises concerns regarding the commercial viability of pegcetacoplan in the ALS market, which is characterized by limited treatment options and high unmet medical need. The competitive landscape includes established therapies like riluzole and edaravone, as well as emerging therapies targeting similar pathways. Investors and stakeholders should consider the implications of this trial's results on Apellis' pipeline and future strategic direction.